# A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

> **NCT03809013** · PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** RC48-ADC

## Key facts

- **NCT ID:** NCT03809013
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2021-03-04
- **Final completion:** 2023-06-05
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809013, "A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03809013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*